VTGN — Vistagen Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1411685 ·
Last close
$0.24
Market Cap
$9.85M
52W High
$0.80
52W Low
$0.20
ADV30
3,231,320
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 465,000 | — | -16,717,000 | -16,274,000 | 48,564,000 | 30,789,000 | 13,044,000 |
| Dec 2025 | 303,000 | — | -19,546,000 | -18,899,000 | 65,056,000 | 47,371,000 | 14,136,000 |
| Sep 2025 | 258,000 | — | -20,053,000 | -19,417,000 | 80,929,000 | 62,786,000 | 14,590,000 |
| Jun 2025 | 244,000 | — | -15,804,000 | -15,095,000 | 68,924,000 | 48,985,000 | 12,159,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-66,436,000
Investing CF
$-877,000
Financing CF
$30,971,000
CapEx
$-239,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.92
As of
2026-06-21
Balance + Analyst (yfinance extras)
Retained Earnings
$-477,317,000
Inventory
—
Receivables
—
ST Investments
$14,614,000
EBIT TTM
$-72,120,000
Pretax Income TTM
$-69,678,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,269,000
EBITDA
$-71,927,000
Free Cash Flow
$-40,496,752
Enterprise Value
$-34,470,180
Total Cash
$45,403,000
Total Debt
$1,044,000
Shares Out
41,032,453
Trailing EPS
$-1.83
Book Value
$0.90
ROE
-131.6%
ROA
-67.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,269,000 | -72,126,000 | -69,685,000 | 48,564,000 | 13,044,000 | — | -66,436,000 |
| Mar 2025 | 486,000 | -55,973,000 | -51,418,000 | 84,341,000 | 13,951,000 | — | -42,097,000 |
| Mar 2024 | 1,064,000 | -33,021,000 | -29,362,000 | 123,653,000 | 9,367,000 | — | -25,813,000 |
| Mar 2023 | -227,000 | -59,268,000 | -59,248,000 | 21,089,000 | 9,009,000 | — | -49,716,000 |
TTM Snapshot
Revenues TTM
$495,000
NetIncome TTM
$-17,083,000
OpCashFlow TTM
$0
Assets (Latest)
$84,341,000
Forward EPS
$-1.54
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TOVX | Theriva Biologics, Inc. | $9.64M | $0.21 | — |
| XCUR | EXICURE, INC. | $10.20M | $1.60 | — |
| BFRG | BullFrog AI Holdings, Inc. | $10.29M | $0.56 | — |
| MCUJF | MEDICURE INC | $9.29M | $0.89 | — |
| GTBP | GT Biopharma, Inc. | $10.60M | $0.29 | — |
News headlines (Yahoo Finance, 1h cache)
Vistagen Appoints Douglas J. Williamson to its Board of Directors
2026-07-31 12:30 · Yahoo
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?
2026-07-15 09:22 · Yahoo
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
2026-06-30 12:00 · Yahoo
HealthEquity (HQY) Q1 Earnings and Revenues Top Estimates
2026-05-28 21:40 · Yahoo
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
2026-05-20 12:15 · Yahoo
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?
2026-05-19 11:08 · Yahoo
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates
2026-05-18 13:00 · Yahoo
VistaGen Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-02-13 13:30 · Yahoo
Vistagen Therapeutics Inc (VTGN) Q3 2026 Earnings Call Highlights: Progress in Clinical Trials ...
2026-02-13 05:02 · Yahoo
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates
2026-02-12 22:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.